Literature DB >> 12951351

Characteristics of French methicillin-resistant Staphylococcus aureus isolates with decreased susceptibility or resistance to glycopeptides.

Névine El Solh1, Marilyne Davi, Anne Morvan, Hélène Aubry Damon, Nicole Marty.   

Abstract

According to the French Society of Microbiology, Staphylococcus aureus isolates are suspected to have decreased susceptibility to glycopeptide(s) when at least one colony is able to grow from an inoculum of 10 microL of 2 McFarland bacterial suspension plated on Mueller-Hinton agar containing 5 mg/L teicoplanin and incubated for 48 h at 35-37 degrees C. We analysed 89 methicillin-resistant S. aureus isolates (MRSA), collected in 2000-2001 from 24 hospitals located in 18 French cities, which were able to grow on this selective medium. These isolates were distributed into six groups on the basis of their glycopeptide resistance phenotypes: (A) glycopeptide susceptible (GSSA, 21 isolates); (B) heterogeneous teicoplanin intermediately resistant (hetero-TISA, 24 isolates); (C) heterogeneous and intermediately resistant to both glycopeptides, teicoplanin and vancomycin (hetero-GISA, six isolates); (D) heterogeneous vancomycin intermediately resistant/teicoplanin intermediately resistant (hetero-VISA/TISA, 30 isolates); (E) GISA (four isolates); (F) TISA (four isolates). Despite the persistent decrease in gentamicin-resistant MRSA isolates in French hospitals since 1993, their prevalence is very high in groups D, E and F. Moreover, most of the group C, D and E isolates exhibiting decreased susceptibility to both glycopeptides belong to the same major SmaI genotype, which has been detected in Europe since at least 1989.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12951351     DOI: 10.1093/jac/dkg400

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant Staphylococcus aureus with linezolid.

Authors:  M Souli; K Pontikis; Z Chryssouli; I Galani; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-11       Impact factor: 3.267

2.  High prevalence of teicoplanin resistance among Staphylococcus epidermidis strains in a 5-year retrospective study.

Authors:  François Trueba; Eliane Garrabe; Rachid Hadef; Roland Fabre; Jean-Didier Cavallo; Krassimira Tsvetkova; Olivier Chesneau
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

3.  Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.

Authors:  Guiqing Wang; Janet F Hindler; Kevin W Ward; David A Bruckner
Journal:  J Clin Microbiol       Date:  2006-09-06       Impact factor: 5.948

Review 4.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

5.  A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA).

Authors:  Andreas Voss; Johan W Mouton; Erika P van Elzakker; Ron G Hendrix; Wil Goessens; Jan A Kluytmans; Paul F Krabbe; Han J de Neeling; Jacobus H Sloos; Nefise Oztoprak; Robin A Howe; Timothy R Walsh
Journal:  Ann Clin Microbiol Antimicrob       Date:  2007-09-24       Impact factor: 3.944

6.  Teicoplanin as an effective alternative to vancomycin for treatment of MRSA infection in Chinese population: a meta-analysis of randomized controlled trials.

Authors:  Yang Peng; Xiaohua Ye; Ying Li; Tao Bu; Xiaofeng Chen; Jiaqi Bi; Junli Zhou; Zhenjiang Yao
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.